Equity Overview
Price & Market Data
Price: $2.25
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $160,403,600
Daily Volume: 0
Performance Metrics
1 Week: 12.50%
1 Month: -10.00%
3 Months: 18.42%
6 Months: 5.63%
1 Year: 44.23%
YTD: 21.62%
Company Details
Employees: 108
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.